Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 96, Issue 4, 2006, Pages 600-605

  Yoshihiro, Ohashi ^a   Yoshinori, Nakai ^b   Kiyotaka, Murata ^c  

^a Ishikiriseiki Hospital   (Japan)

^b KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^c KINDAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE; HOUSE DUST ALLERGEN; POLLEN EXTRACT;

ADULT; ALLERGIC RHINITIS; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOTHERAPY; JAPAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC DISEASE; SYSTEMIC REACTION;

EID: 33645973277     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63556-9     Document Type: Article

References (28)

1. Bousquet J, Van Cauwenberge P, Khaltaev N; ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(suppl): S147-S334.
2. Thoracic Society of Australia and New Zealand. Specific allergen immunotherapy for asthma: a position paper of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. Med J Aust. 1997;167:540-544.
3. Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy. 1998;53:461-472.
4. Moreno C, Cuesta-Herranz J, Fernandez-Tavora L, et al. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy. 2004;32:527-531.
5. Ragusa VF, Massolo A. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods. Allergy Immunol (Paris). 2004;36:52-55.
6. Ohashi Y, Nakai Y, Tanaka A, et al. Risk factors for systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Acta Otolaryngol Suppl. 1998;538:113-117.
7. Committee on the Safety of Medicines. CSM update: desensitising vaccines. BMJ. 1986;293:948.
8. Bousquet J, Lockey R, Malling H. WHO Position Paper: allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998;102:558-562.
9. Grammer LC, Shaughnessy MA, Suszko IM, et al. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol. 1984;73:484-489.
10. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? follow-up study in patients with grass pollen rhinitis. Allergy. 1988;43:523-529.
11. Des-Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract: duration of efficacy of immunotherapy after its cessation. Allergy. 1996; 51:430-433.
12. Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol. 1997;100:293-300.
13. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999; 341:468-475.
14. Johnstone DE. Immunotherapy in children: past, present, and future (part I). Ann Allergy. 1981;46:1-7.
15. Nielsen L, Johnsen CR, Mosbech H, et al. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 1996;97: 1207-1213.
16. Brockow K, Kiehn M, Riethmuller C. Efficacy of antihistamine pretreatment in the prevention of adverse rations to Hymenoptera immunotherapy: a prospective, randomized, placebo controlled trial. J Allergy Clin Immunol. 1997;100:458-463.
17. van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30:891-899.
18. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999; 104:927-933.
19. Simons FER, Simons KJ. Peripheral H1-blockade effect of fexofenadine. Ann Allergy Asthma Immunol. 1997;79:530-532.
20. Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 1999;29:163-170.
21. Pratt C, Brown AM, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol. 1999;83:1451-1454.
22. Okuda M. Practice guidelines for allergic rhinitis. Arerugi. 2002;51:541-543.
23. Portnoy J, Bagstad K, Kanarek H. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergen extracts. Ann Allergy. 1994; 73:378-380.
24. Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy. 2000;55:484-488.
25. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy. 2002;32:133-139.
26. Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol. 2001;107:81-86.
27. Rocklin RE, Sheffer AI, Greineder DK. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med. 1980;302:1213-1219.
28. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf. 2000;23:323-332.